Vitaspring Biomedical Co. Ltd (VSBC) Financiero

VitaSpring Biomedical Co. Ltd. engages in the research and development of stem cell applications in regenerative medicine and the establishment of advanced medical research centers and high standard cell production centers. The company is headquartered in Riverside, California and currently employs 0 full-time employees. The company went IPO on 2019-10-01. The firm invests in research and development of stem cell applications in regenerative medicine, establishes advanced medical research centers and cell production centers, and provides GTP standard stem cell preparations for the development of cellular drugs. The GTP Cell Center is the basis for its business, which is cross-domain in biotechnology medical treatment, medicine and medical materials, and focuses on the development of cell medical treatment. Its GTP standard stem cell production center is in Taipei, Taiwan for mass production of its mesenchymal stem cell (MSC), exesome, and cytopharmaceuticals. The company also cooperates with affiliated companies to support the mass production and commercialization of X.MSC-related medical projects.